Relmada Therapeutics, Inc.
RLMD
$3.78
-$0.26-6.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 53.55% | 44.47% | 19.56% | 25.86% | 1.25% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.26% | -51.73% | -47.97% | -26.58% | -37.43% |
| Change in Net Operating Assets | 90.98% | 100.95% | -895.25% | -46.73% | -48.42% |
| Cash from Operations | 59.64% | 51.73% | -38.59% | 14.15% | -43.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.17% | -52.35% | 52.70% | 46.56% | 318.18% |
| Cash from Investing | -58.17% | -52.35% | 52.70% | 46.56% | 318.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -75.13% | -- |
| Cash from Financing | 100.00% | -- | -- | -75.13% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.16% | -72.90% | 1.79% | 191.03% | 92.25% |